Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHIELD DMD: Satralizumab in Pediatric Duchenne Muscular Dystrophy
2024-512383-65-00Phase 2Authorised
- Sponsor
- Roche
- Start
- Sep 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 6
01
Overview
Phase 2, open-label trial of satralizumab in Duchenne muscular dystrophy (DMD) (2 arms), sponsored by Roche. Primary endpoint: Change from baseline to Week 24 in LS BMD Z-score measured by DEXA. Planned start Sep 2024; status: authorised.
02
Drugs
satralizumab
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on 2024-512383-65-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512383-65-00.